CONTACT US: Contact info
|
Citation |
佑介, 一明, 裕子, 整, 純子. J. Jpn. Counc. Traffic Sci. 2016; 15(3): 29-37. |
|
Vernacular Title |
自動車運転に影響を及ぼす医薬品の処方における薬局薬剤師の対応 |
|
Copyright |
(Copyright © 2016, The Japanese Council of Traffic Science) |
|
DOI |
|
PMID |
unavailable |
|
Abstract |
To clarify pharmacy pharmacists' responses to the prescription of drugs whose package inserts prohibit driving, we conducted a questionnaire survey involving a total of 497 pharmacists belonging to the Shiga Pharmaceutical Association between December 1, 2014, and January 15, 2015. As a result, 116 pharmacies provided completed questionnaires. The number of patients driving to pharmacies was considered to be "very high" or "high" by 78.5％ of the pharmacies. More than 50％ of the pharmacies always reminded patients about the influences of the following drugs on driving：antianxiety drugs, hypnotics, antiallergic drugs, agents to treat pain, antiepileptics, antidepressants, antiparkinson drugs, and antidiabetic drugs. When prescribing these drugs to patients aged 18 years or older, most pharmacies asked them whether or not they drove；however, 11 （9.5％） pharmacies did not usually do so. Concerning responses made when drugs influencing driving have been prescribed to patients who drive on a daily basis, 61 pharmacies stated that they provided patients with pharmaceutical education to direct them not to drive while on medication（prohibition of driving）, and 53 pharmacies made choices other than the prohibition of driving. The reasons why the latter did not provide pharmaceutical education directing patients not to drive included the：1） importance of strict medication adherence to treat their primary diseases, 2） no manifestation of expected side effects among patients receiving drugs from before, and 3） disruption of patients' daily and social lives. Our findings suggest that, as the prohibition of driving hinders the daily and social lives of some patients, it is difficult to provide all patients with pharmaceutical education directing them not to drive. Depending on the drug and patient, it may be possible to prohibit them from driving when they begin their medication, and then to allow them to drive with care after confirming their conditions. To facilitate the prescription of drugs influencing driving, it is recommended to design detailed pharmaceutical education manuals that also give consideration to patients' QOL. Language: ja |